BRUSSELS, Nov 17 (Reuters) - Belgian pharmaceutical group UCB (UCB.BR) said on Tuesday it planned to cut around 2 percent of its workforce with a streamlining of activities in Britain and Belgium. UCB, a central nervous system and immunology specialist, said it had informed its works council that 174 positions could go at its Braine-l’Alleud site in Belgium and 44 positions in Slough, England.
The sites employ 1,589 and 645 workers respectively, while UCB’s total workforce is around 10,000.
UCB said it was adapting its research division NewMedicines in both countries and also streamlining support services, industrial development and administrative functions at Braine.
UCB has already cut around 2,000 jobs in a cost-cutting drive called SHAPE, an initiative to focus on key drugs. (Reporting by Philip Blenkinsop; Editing by Dan Lalor)